Pain Management News and Research

RSS

NeurogesX announces $40 million royalty financing agreement with Cowen Royalty

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that that it has entered into a $40 million royalty financing agreement with Cowen Healthcare Royalty Partners, L.P. ("Cowen Royalty").

30 Apr 2010

Mass. legislation to push poor seniors into managed care plans stirs concerns

Legislation that could push more than 100,000 low-income senior citizens in Massachusetts into managed care health plans spurred intense lobbying yesterday, as consumer advocates argued the measure would strip patients of their freedom to stay in traditional Medicare, while proponents said it could save the state significant money.

29 Apr 2010

PRTT completes acquisition of multiple patents and patents-pending from Nectid

Pro-Tect Pharmaceuticals, Inc. announced that it has completed the acquisition of multiple patents and patents-pending from Nectid, Inc., that enable three revolutionary drug delivery technologies.

26 Apr 2010

Covidien launches EXALGO Extended-Release Tablets in the US

Covidien, a leading global provider of healthcare products, today introduced EXALGO™ (hydromorphone HCI) Extended-Release Tablets, (CII), the only extended-release hydromorphone treatment available in the United States. This proven therapy, combined with an innovative delivery system, provides opioid-tolerant patients suffering from moderate-to-severe chronic pain relief for 24 hours per dose.

26 Apr 2010

Investment report featuring Imaging3

MicroStockProfit.com announces an investment report featuring Imaging3 Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

26 Apr 2010

Physician panel to discuss issues related to Qutenza at Investor Day

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and CEO, and members of the NeurogesX management team, will host an Investor Day on Friday, April 30, 2010, from 8:15am-11:00am EDT in New York City

24 Apr 2010

Need for better understanding potential dangers of prescription painkillers

In response to a study published in the April issue of the American Journal of Preventive Medicine called "Hospitalizations for Poisoning by Prescription Opioids, Sedatives, and Tranquilizers," the Waismann Method of Opiate Detoxification is urging Americans to take measures to better understand and recognize the potential dangers and addictive nature of prescription painkillers.

22 Apr 2010

Clinical success of LOW LEVEL LASER THERAPY to treat FMS reported in Fibromyalgia Aware

Fibromyalgia is a condition in which the brain processes pain in an abnormal way, resulting in chronic, widespread muscular-skeletal pain and chronic fatigue. This condition effects millions of Americans and has been poorly understood and under diagnosed, resulting in billions of dollars in cost to our health care system.

20 Apr 2010

Hospira enters definitive merger agreement to acquire Javelin Pharmaceuticals for $145M

Hospira, Inc., a global specialty pharmaceutical and medication delivery company, and Javelin Pharmaceuticals, Inc., today announced that the companies have entered into a definitive merger agreement providing for the acquisition of Javelin by Hospira for $2.20 per share in cash, or approximately $145 million. Hospira expects to commence a tender offer for all outstanding shares of Javelin common stock on or about April 21, 2010, in accordance with the terms of the merger agreement.

19 Apr 2010

Phase II clinical study examining CTT's Calmare pain therapy medical device completed

Competitive Technologies, Inc. announced today that Thomas J. Smith, MD FACP, and co-investigator Patrick J. Coyne, MSN, APRN, FAAN, of Virginia Commonwealth University's Massey Cancer Center have completed their open Phase II clinical study examining CTT's Calmare pain therapy medical device's efficacy treating patients suffering with severe pain from chemotherapy induced peripheral neuropathy.

15 Apr 2010

Lockheed Martin pledges $4M to aid UCLA Health System's Operation Mend program

The Lockheed Martin Corp. announced today a pledge of $4 million to benefit the UCLA Health System's Operation Mend program, which provides reconstructive surgeries and other health care needs to U.S. military personnel wounded in Iraq and Afghanistan.

13 Apr 2010

Competitive Technologies to introduce Calmare pain therapy at medical conference

Competitive Technologies, Inc. announced today that it will hold a conference for the medical community on May 17, 2010, in Boston, Mass. at the Marriott Long Wharf Hotel from 9:00 a.m. to 3:30 p.m., to introduce CTT's Calmare® pain therapy to the medical community. Professor Giuseppe Marineo, MD, DSc., Researcher, Founding President of Delta Research and Development, Tor Vergata University of Rome, is the Italian inventor of the "Scrambler Therapy," the technology used in the Calmare medical device.

12 Apr 2010

New TIVR telephone system to teach pain management skills to patients with arthritis

Joan Broderick, Ph.D., Research Associate Professor, Department of Psychiatry and Behavioral Sciences at Stony Brook University, has received a $606,000 grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health.

12 Apr 2010

BioAlliance Pharma SA signs partnership agreement with Therabel Group

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces today an exclusive partnership agreement with Therabel Group for the European commercialization rights of Loramyc® and Setofilm® including France and the associated French commercial structure to a newly established entity, Therabel Hôpital Pharma.

6 Apr 2010

Qutenza 8% patch now available for pain associated with PHN: NeurogesX

NeurogesX, Inc. announced today that Qutenza® (capsaicin) 8% patch, the first and only product containing prescription-strength capsaicin, is now available. Clinical studies have shown that a single one-hour Qutenza application can provide three months relief from pain associated with postherpetic neuralgia, the nerve pain that can occur after shingles.

6 Apr 2010

VITAS Innovative Hospice Care begins serving patients with life-limiting diagnoses in Columbus

VITAS, the nation's leading hospice provider, is now serving patients with life-limiting diagnoses and their families in the greater Columbus area, including those in Delaware, Fairfield, Franklin, Licking, Madison, Pickaway and Union counties. VITAS also provides quality, compassionate end-of-life care in Ohio to patients and families in Cleveland, Cincinnati and Dayton.

3 Apr 2010

American Pain Society bestows "Clinical Center of Excellence" on Children's Hospital Boston's Pain Treatment Service

Children's Hospital Boston's Pain Treatment Service has been named a "Clinical Center of Excellence" by the American Pain Society, an honor that is bestowed upon five pain centers each year. This is the first year Children's has entered into the nomination process.

3 Apr 2010

Xanodyne Pharmaceuticals, Ferring Pharmaceuticals sign co-promotion agreement for Zipsor

Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, today announced that it has signed a co-promotion agreement for Zipsor™ (diclofenac potassium) Liquid Filled Capsules with Ferring Pharmaceuticals Inc., a global bio-pharmaceutical company, headquartered in Switzerland.

1 Apr 2010

Tanda Professional Restore light therapy now made available for at-home use

During a press conference yesterday, doctors and experts unveiled a groundbreaking medical device using the healing properties of light therapy for pain management and improving mobility. For the first time ever, a licensed medical device that delivers clinical levels of light therapy only previously available in a doctor's office, has now been made available for at-home use.

1 Apr 2010

Recipients of Pfizer Canada's third Neuropathic Pain Research Awards Competition announced

Pfizer Canada is pleased to announce the recipients of its third Neuropathic Pain Research Awards Competition, which aims to fund and support Canadian innovation within independent neuropathic pain research in the areas of basic biomedical, clinical and health sciences.

31 Mar 2010

Pain Management News and Research

NeurogesX announces $40 million royalty financing agreement with Cowen Royalty

Mass. legislation to push poor seniors into managed care plans stirs concerns

PRTT completes acquisition of multiple patents and patents-pending from Nectid

Covidien launches EXALGO Extended-Release Tablets in the US

Investment report featuring Imaging3

Physician panel to discuss issues related to Qutenza at Investor Day

Need for better understanding potential dangers of prescription painkillers

Clinical success of LOW LEVEL LASER THERAPY to treat FMS reported in Fibromyalgia Aware

Hospira enters definitive merger agreement to acquire Javelin Pharmaceuticals for $145M

Phase II clinical study examining CTT's Calmare pain therapy medical device completed

Lockheed Martin pledges $4M to aid UCLA Health System's Operation Mend program

Competitive Technologies to introduce Calmare pain therapy at medical conference

New TIVR telephone system to teach pain management skills to patients with arthritis

BioAlliance Pharma SA signs partnership agreement with Therabel Group

Qutenza 8% patch now available for pain associated with PHN: NeurogesX

VITAS Innovative Hospice Care begins serving patients with life-limiting diagnoses in Columbus

American Pain Society bestows "Clinical Center of Excellence" on Children's Hospital Boston's Pain Treatment Service

Xanodyne Pharmaceuticals, Ferring Pharmaceuticals sign co-promotion agreement for Zipsor

Tanda Professional Restore light therapy now made available for at-home use

Recipients of Pfizer Canada's third Neuropathic Pain Research Awards Competition announced

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News